Motivational deficits after brain injury: Effects of bromocriptine in 11 patients

Journal of Neurology Neurosurgery and Psychiatry

Volumn 60, Issue 4, 1996, Pages 416-421

  Powell, J H ^a,b   Al Adawi, S ^b,c   Morgan, J ^b   Greenwood, R J ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Abulia; Bromocriptine; Dopamine; Motivation

Indexed keywords

BROMOCRIPTINE;

ADULT; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BRAIN; BRAIN CORTEX; BRAIN INJURY; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; DEPRESSION; FEMALE; FRONTAL LOBE; HUMAN; LIMBIC SYSTEM; MALE; MOOD; MOTIVATION; NAUSEA; PRIORITY JOURNAL; REWARD; SUBARACHNOID HEMORRHAGE; TASK PERFORMANCE;

EID: 0029961117     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.60.4.416     Document Type: Article

References (40)

1. Burgess PW, Alderman N. Rehabilitation of dyscontrol syndromes following frontal lobe damage: a cognitive neuropsychological approach. In: Wood RLI, Fussey I, eds. Cognitive rehabilitation in perspective. London: Taylor and Francis, 1990.
2. Vikki J, Ahola K, Holst P, Ohman J, Servo A, Heiskanen O. Prediction of psychosocial recovery after head injury with cognitive tests and neurobehavioural ratings. J Clin Exp Neuropsychol 1994;16:325-38.
3. Levin HS, High WM, Goethe KE, et al. The neurobehavioural rating scale: assessment of the behavioural sequelae of head injury by the clinician. J Neurol Neurosurg Psychiatry 1987;50:183-93.
4. Ross ED, Stewart RM. Akinetic mutism from hypothalamic damage: successful treatment with dopamine agonists. Neurology 1981;31:1435-9.
5. Echiverri HC, Tatum WO, Merens TA, Coker SB. Akinetic mutism: pharmacologic probe of the dopaminergic mesencephalofrontal activating system. Pediatr Neurol 1988;4: 228-30.
6. Barrett K. Treating organic abulia with bromocriptine and lisuride: four single-case studies. J Neurol Neurosurg Psychiatry 1991;54:718-21.
7. Parks RW, Crockett DJ, Manji HK, Ammann W. Assessment of bromocriptine intervention for the treatment of frontal lobe syndrome: a case study. J Neuropsychiatry Clin Neurosci 1992;4:109-11.
8. Muller U, von Cramon Y. The therapeutic potential of bromocriptine in neuro-psychological rehabilitation of patients with acquired brain damage. Prog Neuro-Psychopharmacol Biol Psychiatry 1994;18:1103-20.
9. Nickels JL, Schneider WN, Dombovy ML, Wong TM. Clinical use of amantadine in brain injury rehabilitation Brain Inj 1994;8:709-718.
10. van Reekum R, Bayley M, Garner S, et al. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 1995;9:49-53.
11. Lindvall O, Bjorkland A, Divac I. Organization of catecholamine neurons projecting to frontal cortex in rat. Brain Res 1978;142:1-24.
12. Robertson A, Mogenson JG. Evidence for a role for dopamine in self-stimuladon of the nucleus accumbens of the rat. Can J Psychol 1978;32:67-76.
13. Bozarth MS, Wise RA. Involvement of the ventral tegmental dopamine system in opioid and psychomotor stimulant reinforcement. Life Sci 1981;28:551-5.
14. Bozarth MS, Wise RA. Heroin reward is dependent on a dopaminergic substrate. Life Sci 1981;29:1881-6.
15. Wise RA. Common neural basis for brain stimulation reward, drug reward, and food reward. In: Hoebel BG, Novin D, eds. The neural basis of feeding and reward. Proceedings from a satellite symposium of the Society for Neuroscience annual meeting, 1981. Maine: Haer Institute, 1982:445-54.
16. Fiorino DF, Coury A, Fibiger HC, Phillips AG. Electrical stimulation of reward sites in the ventral tegmental area increases dopamine transmission in the nucleus accumbens of the rat. Behav Brain Res 1993;55:131-41.
17. Yoshida M, Yokoo H, Mizoguchi K, et al. Eating and drinking cause increased dopamine release in the nucleus accumbens and ventral tegmental area in the rat: measurement by in vivo microdialysis. Neurosci Lett 1992;139:73-6.
18. Pfaus JG, Philips AG. Role of dopamine in anticipatory and consummatory aspects of sexual behaviour in the male rat. Behav Neurosci 1991;105:727-13.
19. Wise RA. Catecholamine theories of reward: a critical review. Brain Res 1978;152:215-47.
20. Thierry AM, Tassin JP, Blanc G, Glowinski J. Selective activation of mesocortical dopaminergic system by stress. Nature 1976;263:242-4.
21. Salamone JD. The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav Brain Res 1994;61:117-33.
22. Weddell RA, Weiser R. A double-blind cross-over placebo-controlled trial of the effects of bromocriptine on psychomotor function, cognition, and mood in de novo patients with Parkinson's disease. Behav Pharmacol 1995; 6:81-91.
23. Liddle PF. The psychomotor disorders: disorders of the supervisory mental processes. Behav Neurol 1993;6:5-14.
24. Brown AS, Gershon S. Dopamine and depression. J Neurol Transm 1993;91:75-109.
25. Goodwin FK, Sack RL. Central dopamine function in affective illness: evidence from precursors, enzyme inhibitors and studies of central dopamine turnover. In: Usdin E, ed. Neuropsychopharmacology of monoamines and their regulatory enzymes. New York, NY: Raven Press; 1974:261-77.
26. van Praag HM, Korf J, Lakke JPWF, Schut T. Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders. Psychol Med 1975;5:138-46.
27. Portin R, Rinnie UK. Neuropsychological responses of parkinsonian patients to long-term levodopa therapy. In: Rinnie UK, Klinger M, Stamm G, eds. Parkinson's disease: current progress, problems and management. Amsterdam: Elsevier, 1980:270-304.
28. Burton K, Calne DB. Pharmacology of Parkinson's disease. Neurol Clin 1984;2:461-72.
29. Levi-Minzi S, Bermanzohn PC, Siris SG. Bromocriptine for "negative" schizophrenia. Comp Psychiatry 1991;32:210-6.
30. Wilner P, Muscat R, Papp M, Sampson D. Dopamine, depression and anti-depressant drugs. In: Wilner P, Scheel-Kruger J, eds. The mesolimbic dopamine system: from motivation to action. New York: John Wiley, 1991:387-410.
31. Blumer D, Benson DF. Personality changes with frontal and temporal lobe lesions. In: Benson DF, Blumer D, eds. Psychiatric aspects of neurologic disease. New York: Grune and Stratton, 1975:151-70.
32. Norman DA, Shallice T. Attention to action: willed and automatic control of behaviour. In: Davidson RJ, Schwartz GE, Shapiro, D, eds. Consciousness and self-regulation: advances in research and theory, (4). New York: Plenum, 1986:1-18.
33. Thorner MO, Vance ML. Clinical aspects of dopamine in the regulation of human anterior pituitary function. In: Fluckiger E, Muller EE, Thorner MO, eds. Basic and clinical aspects of neuroscience. Vol 3. The role of brain dopamine. Basel: Springer Sandoz, 1989:19-29.
34. Shakow D. Psychological deficit in schizophrenia. Behav Sci 1963;8:275-305.
35. Richards PM, Ruff RM. Motivational effects on neuropsychological functioning: Comparison of depressed versus nondepressed individuals. J Consult Clin Psychol 1989;57: 396-102.
36. Wechsler D. Wechsler adult intelligence scale - revised. New York: The Psychological Corporation,1986.
37. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974;11:1019-25.
38. Benton AL. Differential behavioural effects in frontal lobe disease. Neuropsychologia 1986;6:63-80.
39. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiat Scand 1983;67:361-70.
40. Huynh H, Feldt LS. Estimation of the box correction for degrees of freedom from sample data in the randomised block and split plot designs. J Ed Stat 1976;1:69-82.